0.34
-0.0035(-1.01%)
Currency In USD
| Previous Close | 0.35 |
| Open | 0.35 |
| Day High | 0.36 |
| Day Low | 0.34 |
| 52-Week High | 4.17 |
| 52-Week Low | 0.3 |
| Volume | 166,761 |
| Average Volume | 859,911 |
| Market Cap | 17.02M |
| PE | -0.17 |
| EPS | -2.04 |
| Moving Average 50 Days | 0.47 |
| Moving Average 200 Days | 1.11 |
| Change | -0 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $31.1 as of January 16, 2025 at a share price of $0.343. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $19.66 as of January 16, 2025 at a share price of $0.343.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
GlobeNewswire Inc.
Nov 22, 2024 1:16 PM GMT
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-o
BioXcel Therapeutics Announces Proposed Public Offering
GlobeNewswire Inc.
Nov 21, 2024 9:47 PM GMT
NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-o
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
GlobeNewswire Inc.
Nov 12, 2024 12:00 PM GMT
First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Received FDA feedback on protocol for TRANQUILITY In-Care trial of BXCL501 for agitation associated with